Clinical Trials Logo

Filter by:
NCT ID: NCT04249687 Completed - Clinical trials for Lateral Canthal Lines

Treatment of Moderate to Severe Lateral Canthal Lines

READY-2
Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

NCT ID: NCT04249583 Completed - Clinical trials for Glabellar Frown Lines

Treatment of Moderate to Severe Glabellar Lines

READY-1
Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.

NCT ID: NCT04248959 Completed - Osteosarcoma Clinical Trials

Prehabilitation to Improve Cancer Surgery Outcomes in AYA Patients With Extremity Sarcomas

PICaSO-ES
Start date: February 2, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the feasibility of a multimodal prehabilitation intervention intended to optimize postoperative recovery in adolescents and young adults (AYAs) diagnosed with soft tissue and bone-based sarcomas of the upper and lower extremities (extremity sarcomas; ES).

NCT ID: NCT04248920 Completed - Clinical trials for Epilepsy, Generalized

Clinic to Community© Program for Adults With Epilepsy Admitted to Emergency Departments

C2CEDRCT
Start date: September 12, 2022
Phase: N/A
Study type: Interventional

Analysis of emergency department (ED) visits with a billing code for 'epilepsy' or 'seizure' found up to 37% are eligible for deferral. This study is a randomized controlled trial (RCT) of the Clinic To Community© program (C2C) as an intervention for adults with epilepsy visiting emergency departments at a mid size hospital in Ontario, Canada. Participants in the intervention arm receive patient education to improve knowledge of epilepsy and access to community-based services. Participants in the control group are wait-listed and receive patient education 12 months later. The study objective is to successfully implement, recruit and retain participants for this intervention and evaluate whether C2C will reduce the frequency of ED visits, reduce felt stigma and improve quality of life, epilepsy knowledge, and self-management skills.

NCT ID: NCT04248426 Completed - Clinical trials for Hepatitis B, Chronic

A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection

Start date: February 5, 2020
Phase: Phase 1
Study type: Interventional

This is a double-blinded, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and antiviral activity in both healthy volunteers and volunteers with chronic hepatitis B virus infection. Healthy volunteers will be administered either a single oral dose or multiple oral doses of ATI-2173 and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug. Volunteers with a diagnosis of chronic hepatitis B virus infection will be administered multiple oral doses of ATI-2173 and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.

NCT ID: NCT04247776 Completed - Colorectal Surgery Clinical Trials

Pragmatic Prehabilitation for Colorectal Surgery

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Colorectal surgery is a common surgery for the treatment of colon and rectal cancers as well as other bowel diseases. Recovery from colorectal surgery is difficult because of the many potential negative side effects. These side effects include surgical complications, infections, and long hospital stays. It usually takes several months for patients to recover the strength required to return to their typical daily activities. The Enhanced Recovery After Surgery program was established in Alberta in 2013 and uses several strategies to improve short-term patient recovery, including earlier discharge from hospital. Whether the ERAS program also improves long-term patient recovery, including quality of life and return to activities of daily living, is unclear. Whether the ERAS program would benefit from the addition of a prehabilitation element is unclear. Prehabilitation programs are designed to use the waiting period before colorectal surgery to better prepare patients emotionally and physically for their operation. To date, successful prehabilitation programs have used a personalized care strategy where each patient is provided specific care instructions by healthcare professionals to meet their unique exercise, nutrition, and psychological needs. This prehabilitation strategy has been criticized for not being sustainable in our healthcare system. A new prehabilitation program in response to this criticism is proposed. The prehabilitation program will be conducted in a more sustainable way by offering the program as a group class with a home-based component. ERAS patients at the Peter Lougheed Center are already offered a group class as part of the standard ERAS program. The prehabilitation class will be an extension of this group class that provides general nutrition, exercise, and anxiety-reduction/relaxation strategies to help patients prepare physically and emotionally for their operation. At this class, patients will learn to eat well, practice deep breathing exercises for relaxation, perform simple functional exercises, and to walk for exercise before their surgery. The surgical experience and outcomes of patients who received the additional prehabilitation care will be compared to those who received ERAS care only. The overall goal of the study is to better understand how ERAS supports recovery after surgery and whether a prehabilitation program offers any additional benefits to the ERAS program currently in place.

NCT ID: NCT04247139 Completed - Clinical trials for Hypercholesterolemia

Kefir Cholesterol Lowering Pilot Study

Start date: July 7, 2020
Phase: N/A
Study type: Interventional

High cholesterol (a type of fat in humans blood) may be one factor that can lead to heart disease. If people have higher cholesterol, it is possible that kefir (a food similar to yogurt) may help to control blood cholesterol levels.

NCT ID: NCT04247074 Completed - Clinical trials for Glabellar Frown Lines (GL)

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

READY-3
Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.

NCT ID: NCT04245605 Completed - Acute Heart Failure Clinical Trials

Invasive Coronary Angiography Early in Ischemic Heart Failure

ICE-HF
Start date: April 1, 2010
Phase:
Study type: Observational

To compare the outcomes of patients with acute heart failure who undergo early coronary angiography vs. usual care

NCT ID: NCT04245553 Completed - Ascites Clinical Trials

Does Point of Care Ultrasound Change Needle Insertion Location During Routine Bedside Paracentesis?

Start date: February 7, 2020
Phase: N/A
Study type: Interventional

Paracentesis is a bedside procedure in which a needle is inserted into a patient's peritoneum in order to obtain ascitic fluid. This is a safe bedside procedure with very low risks of complications that is usually performed using physical exam maneuvers to determine the site of needle insertion. Point of care ultrasound (POCUS) technology has improved the safety of central venous catheter insertion and thoracentesis, yet the data on safety in paracentesis is equivocal. In a practical study, we aim to determine if POCUS will change the needle insertion site over the traditional anatomic landmarking method. Operators will landmark for paracentesis using conventional physical exam and then utilize POCUS to determine if there is a more optimal site. The primary endpoint will be whether POCUS yielded a change in the needle insertion site, as defined by a location greater than 5cm from the anatomic site, at least 20% of the time. The results will further our understanding of POCUS in improving procedural safety, thereby adding to the currently limited literature on this topic. Furthermore, this study will inform residency training programs about the utility in POCUS training for paracentesis and may advocate for the availability of POCUS devices to physicians performing this procedure.